Cagrilintide news and clinical trials

Researchers published a study showing that daily co-administration of cagrilintide and retatrutide in diet-induced obese male rats produced greater weight loss and improved metabolic markers compared to monotherapies or combinations with semaglutide or tirzepatide.

Novo Nordisk A/S registered a phase 3 study with 210 participants to examine the safety and tolerability of switching from semaglutide to CagriSema in people with type 2 diabetes.

Novo Nordisk A/S completed a phase 1 trial (NCT07605052) that evaluated the blood levels of two different presentations of cagrilintide in 50 participants living with overweight or obesity.

New paper in Annals of medicine and surgery (2012): Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.

Novo Nordisk A/S completed a phase 2 trial (NCT06797869) with 142 participants to investigate the effects of CagriSema compared to a placebo in individuals with type 2 diabetes and painful diabetic peripheral neuropathy.

Novo Nordisk A/S registered a phase 3 comparability study (NCT07745504) with 285 participants to assess the efficacy of two different versions of injectable cagrilintide for weight management in people with overweight or obesity.

Novo Nordisk A/S completed a phase 1 study (NCT06719011) with 178 male participants to assess the safety, tolerability, and pharmacokinetics of NNC0174-1213 compared to cagrilintide and a placebo.

Novo Nordisk A/S completed a phase 3 study of 1023 participants to compare the efficacy of 1.0 mg/1.0 mg CagriSema versus 5 mg tirzepatide for blood sugar and body weight reduction in people with type 2 diabetes.

Researchers published findings identifying specific cellular loci in the brain for the action of the obesity therapy cagrilintide.

Scientists created a transcriptomics atlas of over 530,000 cells in the caudal brainstem to study cagrilintide. Long-term treatment with the drug upregulates prolactin-releasing hormone expression in nucleus of the solitary tract neurons, which mediates its effects on energy balance.

New randomized trial in Lancet (London, England): Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.

The Lancet Diabetes & Endocrinology published an article discussing the potential of the combination therapy cagrilintide-semaglutide for treating type 2 diabetes.

A phase 3 study of 2713 participants with type 2 diabetes and obesity investigated the efficacy of the fixed-dose combination CagriSema versus semaglutide or cagrilintide alone over 68 weeks.

New randomized trial in The lancet. Diabetes & endocrinology: Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase….

A phase I clinical trial published in Clinical pharmacokinetics evaluated cagrilintide in 33 participants with renal impairment and 32 participants with hepatic impairment. Researchers found that impairment did not affect pharmacokinetics, safety, or tolerability of the drug.

New paper in Endocrinology, diabetes & metabolism: Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.

Novo Nordisk A/S registered a phase 1 trial to evaluate the tolerability of Cagrilintide in 114 participants with obesity or overweight who discontinued GLP-1-RA therapies due to gastrointestinal adverse events.

New review in Journal of diabetes and metabolic disorders: Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.

Novo Nordisk A/S registered a phase 1 trial (NCT07605052) enrolling 50 participants to compare the pharmacokinetics of two different versions of cagrilintide injections in adults with overweight or obesity.

Novo Nordisk registered a phase 1 trial for 234 participants to compare blood levels of two versions of cagrilintide, version B and version D, in adults with overweight or obesity. The study aims to understand the effects of these two medicine versions.

Novo Nordisk registered a phase 1 trial for 120 participants to investigate how cagrilintide affects food intake and appetite in people with overweight or obesity. The study will compare cagrilintide against a placebo over approximately 30 weeks.

Novo Nordisk completed a phase 3 trial evaluating the efficacy and safety of CagriSema, a combination of cagrilintide and semaglutide, in 300 participants with obesity. The study assessed weight loss outcomes using weekly 1.0 mg/1.0 mg and 1.7 mg/1.7 mg doses.

New randomized trial in The lancet. Diabetes & endocrinology: Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre….

Novo Nordisk registered a phase 1 trial for 100 participants to examine the effects of CagriSema, cagrilintide, and semaglutide on muscle health in individuals with excess body weight and slightly high blood sugar. The study evaluates skeletal muscle insulin sensitivity, composition, and function.

Novo Nordisk A/S completed a phase 3 trial with 1024 participants comparing the efficacy of CagriSema to tirzepatide in people with type 2 diabetes. The study measured blood sugar and body weight reduction.

A meta-analysis of 3 randomized controlled trials with 3,545 participants evaluated cagrisema and cagrilintide against semaglutide. Cagrisema produced significantly greater weight loss than semaglutide with a mean difference of -7.47% in body weight.

Novo Nordisk registered a phase 1 trial involving 100 participants to study the gastrointestinal tolerability of combining cagrilintide with the GIP receptor agonist NNC0480-0389. The research compares this combination treatment against cagrilintide alone in people who are overweight or obese.

Novo Nordisk completed a phase 1 trial involving 158 participants with type 2 diabetes to investigate how CagriSema, semaglutide, and cagrilintide regulate insulin effects. Participants received the study medicines in combination with metformin.

Novo Nordisk completed a phase 2 trial studying the effects of NNC0194-0499, semaglutide, and cagrilintide, alone or in combinations, on liver damage and alcohol use. The study included 270 participants with alcohol-related liver disease.

Novo Nordisk completed a phase 3 trial comparing the weight loss efficacy of CagriSema against tirzepatide in 809 participants with obesity. The study administered 2.4 mg/2.4 mg of CagriSema or 15 mg of tirzepatide weekly via injection.

Novo Nordisk A/S completed a phase 3 trial (NCT06065540) involving 2734 participants to compare how well CagriSema lowers blood sugar and body weight in people with type 2 diabetes compared to semaglutide, cagrilintide, or placebo.

Novo Nordisk A/S completed a phase 3 study with 189 participants to assess the efficacy of CagriSema doses of 2.4 mg/2.4 mg and 1.0 mg/1.0 mg compared to placebo in people with type 2 diabetes.

Novo Nordisk A/S registered a phase 3 trial to assess the safety and efficacy of CagriSema compared to placebo in 80 children and adolescents with type 2 diabetes.

Novo Nordisk completed a phase 1 clinical trial of 164 participants investigating the effects of the combination treatment CagriSema on appetite and brain activity in adults with overweight or obesity.

Novo Nordisk A/S registered a phase 3 trial with 460 participants to evaluate the efficacy, safety, and pharmacokinetics of Cagrilintide and CagriSema for weight management in children and adolescents with overweight or obesity.

The New England Journal of Medicine published a letter and comment regarding Cagrilintide-Semaglutide in adults with overweight or obesity.

The New England Journal of Medicine published a letter and comment regarding Cagrilintide-Semaglutide in adults with overweight or obesity.

The New England Journal of Medicine published a letter and comment regarding Cagrilintide-Semaglutide in adults with overweight or obesity.

The New England Journal of Medicine published a letter and comment regarding Cagrilintide-Semaglutide in adults with overweight or obesity.

Authors published a letter in The New England journal of medicine discussing cagrilintide-semaglutide for weight management in adults.

Authors published a letter in The New England journal of medicine regarding the use of cagrilintide-semaglutide in adults with overweight or obesity.

Novo Nordisk A/S completed a phase 2 clinical trial (NCT06131372) involving 626 participants to assess if CagriSema reduces kidney damage in people with chronic kidney disease, type 2 diabetes, and obesity.

Novo Nordisk A/S registered a phase 3 study (NCT07220642) enrolling 300 participants to evaluate the efficacy and safety of cagrilintide for weight management in individuals with overweight or obesity.

Novo Nordisk A/S registered a phase 3 trial for 330 participants to evaluate the efficacy and safety of Cagrilintide for weight management in individuals with type 2 diabetes and obesity or overweight.